ESRD Clinical Trial
Official title:
Blood Flow Effects on Silicon Substrates
This is a non-randomized, open label, uncontrolled first in human safety study, testing the
the material used in the artificial kidney device in subjects already on hemodialysis.
Six subjects already on hemodialysis, who meet the study inclusion and exclusion criteria,
and who dialyze at one of the UCSF associated hemodialysis units will be recruited. Each
subject will be tested during one non hemodialysis day, at the UCSF Moffitt-Long Hospital
Acute Hemodialysis Unit (AHU).
The artificial kidney engineers have created a blood flow system that can be substituted for
the dialysis filter in a standard hemodialysis machine. This is NOT a dialysis filter. It
allows the subjects blood to come in contact with the material while the blood is being
circulated as is regularly done during a hemodialysis session.
For patient safety, the investigators will measure the following labs:
Blood tests (routine safety and frequency). CBC/platelets: q 1 hr, at HD next day ABGs,
including lactate: Q 1 hr x 6 Na, K, Cl, Bicarb, BUN, Creatinine, Ca, ionized Ca, Mg, Phos:
Start, end, at HD next day Liver function test: Start, end, at HD next day LDH: Start, end,
at HD next day Direct Coombs' Test: Start, end, at HD next day ESR and hsCRP: Start, end, at
HD next day CPK: Start, end PT/PTT: Start, end
The investigators will also be doing research blood testing:
IL-6: Start, end, at HD next day Complement: Start, end, at HD next day Haptoglobin: Start,
end, at HD next day Free Hg: Start, end, at HD next day Fibrinogen, D-dimer: Start, end, at
HD next day
In addition, the investigators will do material testing after each participant's test is
complete.
Material studies after in vivo testing :
Cell and Protein Adhesion Studies:
1. Scanning Electron Microscopy. The SNM will be placed in a solution containing 2%
glutaraldehyde (Electron Microscopy Sciences, Fort Washington, PA), 3% sucrose (Sigma
Aldrich) and 0.1 M of phosphate buffered saline (PBS) at 4°C and pH 7.4. After 1 hour,
the substrates are rinsed twice with PBS for 30 minutes at 4°C and washed with distilled
water for 5 minutes. Dehydration is achieved by placing the substrates in 50% ethanol
for 15 minutes while increasing the concentration of ethanol to 60%, 70%, 80%, 90%, and
finally 100%. Dehydrated samples are then mounted on aluminum stubs, sputter-coated with
gold-palladium, and examined using Scanning Electron Microscopy (SEM; Ultra55 FEGSEM,
ZEISS, Peabody, MA).
2. Immunohistochemistry. Platelet adhesion and activation are assessed using
immunofluorescence staining for the platelet marker, CD41 (Abcam, Cambridge, MA), and
blood-clot marker, tissue plasminogen activator (t-PA, Abcam, Cambridge, MA). Platelets
are fixed in 4% paraformaldehyde (Fisher Scientific, Waltham, MA) for 15 minutes
followed by incubation in 1% bovine serum albumin for 30 minutes to block nonspecific
binding. Platelets are double-labeled as follows: substrates were first incubated with
primary antibodies (t-PA), diluted 1:50 in PBS for 60 minutes followed by Alexa Fluor
546 donkey anti-mouse antibody (Invitrogen, Carlsbad, CA) diluted 1:100 in PBS for 60
minutes. Finally, the samples are incubated with anti-human CD41 fluorescein
isothiocyanate labeled mouse monoclonal antibody diluted 1:300 in PBS for 60 minutes.
Images will be acquired per replicate using a Nikon Eclipse Ti-E motorized inverted
microscope (Nikon Instruments Inc., Melville, NY) to obtain a total of 12 images per
substrate. The fluorescent intensity of the images is quantified using ImageJ.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03246984 -
VALUE- Vascular Access Laminate eUropean Experience. A Post Market Surveillance Study to Assess the Safety and Effectiveness of VasQ
|
N/A | |
Completed |
NCT03943212 -
The Effect of Blood Flow Rate on Dialysis Recovery Time in Patients Undergoing Maintenance Hemodialysis
|
N/A | |
Completed |
NCT03456648 -
Apixaban in End-stage Kidney Disease : A Pharmacokinetics Study
|
Phase 2 | |
Completed |
NCT01252771 -
Phosphate Kinetic Modeling 2
|
Phase 4 | |
Completed |
NCT00966615 -
The Effect of Neutral Peritoneal Dialysis (PD) Solution With Minimal Glucose-Degradation-Product (GDP) on Fluid Status and Body Composition
|
Phase 4 | |
Completed |
NCT00850252 -
Use of a Lifeline Graft in the A-V Shunt Model
|
Phase 1/Phase 2 | |
Completed |
NCT00294502 -
Antibiotic Lock Solutions in the Prevention of Catheter Related Bacteremia
|
Phase 4 | |
Completed |
NCT05011136 -
Physician Reimbursement Home Patients
|
||
Completed |
NCT05144971 -
StatStrip A Glucose/Creatinine Meter System Lay User Study Evaluation
|
||
Completed |
NCT02278562 -
Nutrition, Inflammation and Insulin Resistance in End Stage Renal Disease-Aim 2
|
Phase 2 | |
Completed |
NCT01424787 -
Non-interventional Study to Evaluate the Ease of Reaching Individual Goals in Serum Phosphorus (Steering)
|
N/A | |
Terminated |
NCT00580762 -
Bariatric Surgery for ESRD Patients vs Control
|
N/A | |
Recruiting |
NCT05339139 -
SAfety of Regional Citrate Anticoagulation (SARCA Study)
|
Phase 3 | |
Completed |
NCT03242343 -
VasQ External Support for Arteriovenous Fistula
|
N/A | |
Recruiting |
NCT05309785 -
Safety and Efficacy of Canagliflozin in Advanced CKD
|
Phase 4 | |
Completed |
NCT02966028 -
Effect of SNF472 on Progression of Cardiovascular Calcification in End-Stage-Renal-Disease (ESRD) Patients on Hemodialysis (HD)
|
Phase 2 | |
Completed |
NCT02513303 -
Trial to Evaluate the Sirolimus-Eluting Collagen Implant on AV Fistula Outcomes
|
Phase 3 | |
Not yet recruiting |
NCT02596386 -
Examination of Potassium Levels in Saliva in ESRD Patients
|
N/A | |
Active, not recruiting |
NCT02270515 -
Bringing Care to Patients: Patient-Centered Medical Home for Kidney Disease
|
N/A | |
Recruiting |
NCT06001827 -
SAVE-FistulaS: the SelfWrap-Assisted ArterioVEnous Fistulas Study
|
N/A |